JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - VAXCYTE INC
All right. Welcome, everyone, to Jefferies' 2026 Global Healthcare Conference in London. My name is Roger Song, senior at Kavasimika Biotech in the U.S. It is my great pleasure to have the fireside chat with Vaxxai. And then we have CEO Grant Bickering, we have CFO Andrew Guggenheim, and then we'll have Chief Commercial Officer Mike Mullet. Welcome, gentlemen. Thank you, Roger. Excellent. Why not, Grant? You start with the state of art of VACCIDE. You already reported very impressive home-run data from the pneumococcal vaccine in adults, and then you're expecting from the infant data pretty soon, early next year. So give us some high-level overview, and we can dive into the conversation. Yeah, well, first of all, thank you for having us here to the conference. And And yeah, the state of the union for Vaxcide is very strong. Right now, we have recently obtained the pivotal results for our first phase three study with Vax 31, which is the broadest spectrum pneumococcal conjugate vaccine that's been advanced into the clinic. It was a rousing success. We compared Vax31's immune responses to the two standard of care vaccines that are currently available today. One is a 20-valent vaccine. The other is a 21-valant vaccine. And we met all of the endpoints for that study, setting us up to put a BLA in place in the first half of 2028. We couldn't be more excited about the results we have delivered on the paradigm shift that we believed was possible, which was to expand coverage to protect against more disease without seeing a degradation in the immune responses, which has been a hallmark of the tradeoffs to obtain broader coverage in the past in this class. So Vax31 is the lead program that the company has been advancing. We now have those pivotal results in adults. We will be in receipt of the phase two data for Vax 31 in infants, which is the other part of this market in the first half of next year. And beyond that, we also have another vaccine in the clinic, group A strep, which a novel vaccine that also has blockbuster opportunity, white space, but still another promising program, and I'm sure we'll get into a lot more details on the PCB class over the course of this conversation. Excellent. Thank you. Maybe we'll just talk about the adult for the first moment, and then I believe the only outstanding trial used to initiate for the phase three program is CMC consistency. give us some updates on that, and then what's the blocking and the tackling you need to do before you can start, and how does that still align with the BLA filing timeline? Yeah, so the BLE for Vax31 for adults is going to consist of four different phase three clinical studies, the one of which I've already referenced. The pivotal study that's done, that'll be the cornerstone of the BNA filing. There are two other phase three studies that are fully enrolled that we'll read out in the first half of next year. There are two complementary studies. We'll get into the details, I'm sure. And then the last study will be a manufacturing consistency study, which is par for the course in this class. It will consist of some number of batches of Vax31 compared in normal healthy 18 to 49-year-olds, for which you look to show non-inferior immune responses across these different batches. This is standard procedure in vaccine development. That program will be locked down in due course and will be the last of the four studies that comprise the BLA filing. So we expect to have details on that in the not too distant future and to be launching that study sometime in 2027 to have it read out in time for that BLA filing in the first half of 2028. Okay. All right. Good. And then I just want to also confirm this CMC, the lots, is it coming from the commercial supply, and which facility it is actually coming from, and then how much you need to do there? Yeah, so we have been manufacturing with our partners at Lonza for some time, and this manufacturing consistency study will be made up of materials that have been made at Lonza in the multi-use facility for which we've been manufacturing over time. There is a second facility that Roger is referencing that is already fully built out, operational, and is manufacturing vaccine as we speak, but this study will not include material from that study yet. That will be a follow-on effort that will unlock that larger capacity post-launch. Okay, got it. And understanding the BLA filing still targeting on track for first half of 2028, is that any kind of possibility you will start to rolling submission while you're waiting for additional study coming from, because you already read out the first, the most important thing if you already immediately study? Yeah, so the base case for us is to do a BLA filing in one fell swoop. There is certainly the possibility that we shift to a rolling submission for which we could submit some of the clinical data prior to the last of the materials that we go in. If we believe that there is a benefit to that, we will pursue that path. But for the time being, we are sticking with a fulsome filing in a one fell sweep. Excellent. Okay. As you mentioned earlier, you have two other phase three, Opus 2 and Opus 3. And then I think they add very unique features to the whole profile. Maybe just give us some, you know, the highlights in terms of Opus 3, Opuse 2. So why you think that's important and then how you will think about the data will enhance the profile overall. Yeah, maybe I can start with Opus 1 and I'll let Mike talk about Opus 3. Opus 2 is a study where we are concomitantly administering Vax 31 with a seasonal flu vaccine. This is to provide the data that will demonstrate the ability to give these vaccines simultaneously so as to create the convenience of protecting individuals against more than one potential pathogen at the pharmacy level. This standard operating procedure in vaccines. In the context of how this will fit into the ecosystem, Capvaxiv, the 21-valent standard of care product, they launched with that information in their BLA filing. Prevnar20 followed with that post-launch. We'll have that as part of the evidence that we'll be able to provide decision makers in the contextof our BLA. Opus 3 is a little bit more valuable from a marketing perspective. So, Mike, why don't you take that one? Yeah, I think Opus really provides the opportunity for us to have data to support revaccination for patients who've received a previous PCV vaccine. So what that means for PCV vaccination in general in the marketplace is when Vax31 comes to market, there'll be a question that healthcare providers need to ask is, should I update this patient who had received PCV20 or perhaps PCV21 or perhaps even PCV13 or PPSV23 in the past. So these data will provide us the opportunity to answer that question and support revaccination recommendations, which are recommendations that we would expect to have good conversation with the recommending bodies on during post-approval. So this will obviously open up a large market opportunity for us to address that patient population who's already been immunized and catch them up with Vax31. And Mike, I might just add that that dynamic already exists in the market today, where, for example, PCV20, it has essentially what is a pocket preferred recommendation to revaccinate subjects with PCV21 who prior received a less-surveillant vaccine. So there is certainly precedent in the market for this, and the study, we believe, would enable us to get a similar preferential recommendation. Excellent. Okay, great. A little bit fast forward, you know, you read out all of those sort of phase three study and positive, and then you file bill, and you get approval. So what's the ramp up going to look like? I'm not talking about the sales guidance, just in terms of the logistic and then all the procedure as you get an FDA approval, because this is a vaccine launch, right? So you may need to get the ACIP recommendation, set up a lot of the contracting or the channel setup, and then how we think about the ramp going to work like. Yeah. So I'm going to hand that to Mike in one second, but we hired Mike, our chief commercial officer a little over a year ago, given his experience having worked at Sanofi vaccines for quite some time and having a role in introducing Moderna's first vaccine as well. So he's no stranger to launching vaccines in the U.S. and globally. So we're delighted to have him on the team. And maybe you can give a little primer on how you're thinking about things. Sure. So maybe a few things just to kind of break down. Maybe first, Roger, would be about recommendations. And then second would be around kind of the access components. So from a recommendation perspective, we will, of course, be working with the ACIP. Obviously, today, we know that the AC IP is not functioning as it has in the past. But the good news is the other recommending bodies, AMA, Vaccine Integrity Project, AAFP, have all been coordinating their efforts to ensure vaccination exists, you know, recommendations exist, but also that health care coverage exists in the United States as well. So we've been pleasantly surprised by the coordination of that effort and the market response. We've seen that in influenza season, for example, this year, so we feel very good about that. So we will either work with ACIP or these independent bodies, you know, kind of one-by-one basis, and that's already started, so that we feel really good about it. We feel very confident about, you now, kind-of where we are in that approach. As for the adult immunization market, I think really helpful for folks to understand the adult immunization Market in the United States where we will start our launch is highly concentrated. We have retail pharmacies and large health systems which make up over 75% of the immunization for adults in the united states and those bodies have a very tried and true path of engagement for setting up vaccination contracts. So the Walgreens and the CVSs of the world, as well as the health systems like Cleveland Clinic or others, have people in place who are used to first recommending the vaccinations that they want to use through a P&T committee or through a medical committee, and then secondly, contracting to acquire those vaccines. As a first-time launcher, that's very advantageous for us because we're talking about maybe 200 accounts in the United States or so that we need to manage for the adult launch. And we already have people in place starting that engagement process where appropriate and early to understand how we engage, especially medically, so far. So that's kind of where we are right now and the path we see moving forward. And Roger, I might just kind of remind the market into which we're entering here, right? You've got a global market that is about $8 to $8.5 billion in total. That's comprised today about a third in the adult population, so 2.5, 3 billion in the adult market. The overwhelming majority of that adult market is in the United States today. Europe and the rest of the world is just coming online with adult recommendations. Of course, the balance is comprised of infants, so today you're a third adult, two-thirds infant, but the substantial growth in the market from 8.5 billion today, it's expected to grow to 12 billion or larger in the next five, six years. That growth is really driven by the adult market, So in the future, the expectation is that the global market of 12 billion or so in size will be comprised closer to half adult and half of infant. So excited about the opportunity, not only here, well, in the U.S., but also here in the rest of the world as these other countries are beginning to make recommendations for the first time to vaccinate their adult populations. Excellent. And then just one follow-up on the Dow. And then we know your potential approval is by the end of 2028, and then you will start to do the launching and then set up and then work starting 2029. So do we have, like, any set time you can do those kind of contracting or there's a rolling base with those retail and the large institution because you want to launch this soon after the approval? Yeah, so obviously we'll want to get going as soon after approval as possible. Most contracts allow for innovation to open the contract. So if there was a contract between a health system and another vaccine manufacturer, do we have the opportunity to participate in that contract? The answer is yes. These typically have openings for innovation. So when we have a new product licensure or approval, that we're able to start those discussions. So there's a lot of precedent for that as well. How long is it going to take? Because, you know, for the Wall Street, how are we going to model your 2029 revenue versus the 2030 revenue? Yeah, so, you Know, I don't think we're at the point where we're guiding to revenue yet. But what I would say is there are previous PCV vaccine launches that have been very successful in recent past, that would allow you to sort of take a barometer of how quickly vaccine market share can happen. I'll refer back to Capvaxiv, who I think had a really strong start to their launch. In the first 12 months, they were a little over 45% market share, a lot of that driven by uptake in the retail pharmacy segment. So I think it's reasonable to assume that in the PCV space, there's a rapid movement to the broader serotype coverage vaccines. So we've seen that time and time again from PCB 7 to 13 to 15 to 20 to 21, and again at 31. Excellent. Okay, great. Last question related to the adult. I think, Andrew, you mentioned earlier in terms of the growing market opportunity for adult. So we know the growth probably coming from different pocket, right? And then one of the bigger part, you know, when a big pocket is not yet really happening now, it's a revaccination, because we know right now is one dose for everyone. But because they lower the age group to 50, likely we're going to use another one. So what's the current thinking about? First of all, immunity, what can, you know, what really scientifically driving the second dose, when? And then what's health economic? Because we see a lot of discussion at the ACIP already, but seems the health economics does not justify, you know, we get another dose, but maybe with the higher valency vaccine, and then maybe that's justified. So what's the thinking, what's the data you have right now to support that? Yeah, it's a good question. I would call that a work in progress. When this was last debated at the ACIP level, this was in the context of the 21 valent from Merck Capvaxiv having just been approved, and there was a recognition at ACIP that with this lowering of the age to age 50 for initial pneumococcal conjugate vaccination, it opened the door for a subsequent vaccination as people get older, begin to immunosenes, and the effect of the vaccine could wane. I think the reality is there was not a lot of clear data that would demonstrate precisely how long these vaccines will protect older adults. Clearly, there's a benefit to beginning to protect individuals sooner in their lives, so that change was made, and there was an explicit discussion about when to revisit this topic, and the decision was taken that they would wait until the context of higher valent vaccines being introduced, and they explicitly referenced both Vax24, our predecessor vaccine, and Vax31, the vaccine for which we expect to bring to market. So we do believe there will be an opportunity for that to be revisited in the context of Vax 31's approval. And we will have some time to begin to prepare to make that case along with the ACIP interested parties. And I believe that will be the key data package you will submit it to the ACIP once you get approval and then that will be the part of the discussion you will try to fight for. Yeah and there is already evidence that shows that more than one vaccination to adults does produce a boost in that second administration which would suggest the benefit at minimum and we'll see what else we can pull together to make the case awesome all right so let's talk about the infant because that is one of the key debates and among the investors because this is the next key data updates you will provide to us and then we know the totality right because in the previous all the approval for infant and adult pcv so none of them are perfect right so you're always going to look at the the totility so just give us some updates because the phase three, the pivotal for infants seems to bar a little bit higher for PD4, and then when you read out the phase two data in first half next year, so will be considered as a good result. You can confidently move into the phase 3. Yeah, so we already have a fully enrolled infant study with VAX31 that we've guided to seeing the results in the first half of next year, by the end of the first half of next year is when we expect to put out the full data for that study. We are comparing Vax31 to the current standard of care, which is Prevnar 20. And Roger, it was a very good setup. In this class, the trade-offs for expanded coverage have historically included some non-inferior comparisons for the overlapping serotypes in the new vaccine, along with the current Standard of Care vaccine. So these precedents have been set in the context of the current standard of care there were six missed non-inferior immune endpoints for which were adequate to serve as the basis for the approval of that product so we certainly don't expect to be perfect when you're stretching from a standard ofcare that's at 20 to a product like vax 31 where we're adding 11 serotypes on top of the same foundational 20 so the expectations that we have been setting is that we expect to see something similar to what we saw with our 24 valent vaccine in infants that read out last year, but for the fact that we have two significant differences. One, VAX31 has obviously got seven more serotypes. The hurdle for the incremental serotypes over and above the 20 valent is frankly a little bit lower because you're comparing yourself to the second lowest performing serotype in Prevnar 20. So we have very high confidence that those incremental 11 will exceed the threshold required And that's really where the primary benefit comes from, the coverage that Vax31 confers, which is in the 90-plus percent of circulating disease, compared to Prevnar 20, which is around 60 percent, naturally comes from those incremental 11. So that is the big hook that will pull this product through. And then there are really the 20 overlapping serotypes, which I put in two different categories, those that are currently circulating in relevance and those that are not. And what we had seen with VAX24 was that we did extremely well on those serotypes that are still circulating. And so we feel good about the expectations there. And the misses that we had seen with Vax24 in all but one case were in serotypes, that had no longer circulated for some time. So they are of the least strategic import. So when we look at setting those expectations, we expect to see something similar with Vax31. The FDA will look at the totality of what this vaccine can provide relative to the standard of care. So I talked about the one big difference being the incremental 11. The other big difference is that we are testing higher doses of Vax 31 than we had tested with Vox 24. We've seen a very clear dose response with regard to generating higher immune responses with higher doses of the vaccine. So we do expect to see improvement in the immune responses on a relative basis with these higher doses in Vax31. So yes, the bar did go up for the second of the two co-primary endpoints with regard to the non-inferiority standard, but we do think that we'll see improvement with regard to the immune response with these high doses. So, we think that will be, you know, perhaps So net neutral, perhaps still a win in our favor on a relative basis to the VACS-24 results. Excellent. Okay, one operational decision to make is if you will break out or combine the PD-3 and the PD4 readout together. So what's the strategic or tactical consideration, and when and how are you going to let us know how you're going to release that? Yeah, just to level set, I think as folks know, we've continued to maintain this optionality to either unblind unblind both the primary series data, which is after the first three doses of the vaccine, concurrent with the booster data, after the fourth dose. We maintained the optionality to unblind those data sets concurrently, in which case we announced them at the same time, or to unwind the data sets sequentially, in the case we had announced the primary data prior to the booster. We have been very clear in our guidance as well that we continue to lean toward the concurrent And the real decision, Roger, is, you know, do we see any material operational benefit from an earlier unblinding that would allow us perhaps to advance into phase three more quickly, engage with the FDA more rapidly? We haven't seen that yet, which is why we continue to lean toward the concurrent approach. We expect by the early part of next year to kind of answer that question definitively and let the market know what the plan is and the associated timing with that. Excellent. Okay. You know, this has been pretty dominated by a couple of big players, and then we recently see five reported 25-valent infant data. So it is pretty good on the certain serotypes, including the serotype 3. So we talk about the totality, right? So let's say Vax31 have a 31-valence versus the maybe other ones that are a bit higher than the current 20. So, how should we think about this serotype 3 versus the totality of the immunogenicity? So what's the tradeoff you think the physician and then the market will make if, let's say, you are a little bit lower on the serotype 2, because I think if I focus on that one and then, the number is relatively high. Yeah. So, in this class, it has been a very clear track record of success. included conjugates in the marketed vaccines have largely been taken out of circulation upon introduction and widespread vaccination. The lone exception to that is serotype 3. So serotype three has a different physical chemical set of properties that allow it to elude the traditional antibody generation clearance of this bacterium. So that is one that has been included in the marketed vaccines for 16 years, and yet it is the highest circulating serotype still. So there's clearly something going on there. Unfortunately, there have been vaccines that have been introduced and marketed with higher relative antibody responses against serotype 3. Unfortunately, it hasn't produced anything meaningful from a clinical perspective, and that's been proven recently. So that is just a really recalcitrant serotype, which unfortunately we've not cracked the code on. So it's true that Not only with the 15-valent from Merck, the 21-valents from Merk, they have generated higher antibody responses, just unfortunately hasn't translated into a meaningful impact. That is what Pfizer has been attempting to do with the 25-valet that's in development. They've shown higher antibody response as yet. It's just still unclear as to whether or not that's going to make any meaningful clinical difference. It's clearly a step in the right direction. It just hasn't proven to be a meaningful differentiating feature yet in this class, and so that's the state of play at the moment. Got it. And I just might add from a commercial standpoint as well, we've seen this play out before. Merck's VaxNuVance, which is a 15-valent, had statistically higher serotype 3 responses and got to market and began to get traction, and then Pfizer launched Revnar20 with a lower serotype 3 response, and it reasonably quickly captured over 90% of the market simply because this market has been about broader coverage is better. So the higher serotype-3 response for a lesser valent vaccine didn't translate to commercial benefit, and as Grant said, has been proven also not to translate to clinical benefit yet. Excellent. All right. Time flies, and great talk, and thank you so much for the team, and I thank everyone for listening and watching. Thanks, Roger. Thank you. Appreciate it. All right, thank you. Thank you.
- Company
- VAXCYTE INC
- Keywords
- VAXCYTE INC